blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3698792

EP3698792 - DOSING REGIMENS FOR THE TREATMENT OF FABRY DISEASE [Right-click to bookmark this link]
StatusExamination is in progress
Status updated on  31.05.2024
Database last updated on 08.04.2026
FormerRequest for examination was made
Status updated on  05.03.2021
FormerThe application has been published
Status updated on  24.07.2020
Most recent event   Tooltip06.01.2026New entry: Renewal fee paid 
Applicant(s)For all designated states
Amicus Therapeutics, Inc.
3675 Market Street
Philadelphia, PA 19104 / US
[2021/14]
Former [2020/35]For all designated states
Amicus Therapeutics, Inc.
1 Cedar Brook Drive
Cranbury, NJ 08512 / US
Inventor(s)01 / GREENE, Douglas Stuart
15 Liberty Street
Newton, PA Pennsylvania 18940 / US
02 / VALENZANO, Kenneth Joseph
337 New Brunswick Avenue
East Brunswick, NJ New Jersey 08816 / US
 [2020/35]
Representative(s)Hoffmann Eitle
Patent- und Rechtsanwälte PartmbB
Arabellastraße 30
81925 München / DE
[N/P]
Former [2020/35]Miller Sturt Kenyon
9 John Street
London WC1N 2ES / GB
Application number, filing date20160164.808.03.2012
[2020/35]
Priority number, dateUS201161451798P11.03.2011         Original published format: US 201161451798 P
US201161578201P20.12.2011         Original published format: US 201161578201 P
US201261596165P07.02.2012         Original published format: US 201261596165 P
[2020/35]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP3698792
Date:26.08.2020
Language:EN
[2020/35]
Search report(s)(Supplementary) European search report - dispatched on:EP09.07.2020
ClassificationIPC:A61K31/445, A61K38/47, A61P3/00, A61K9/48
[2020/35]
CPC:
A61K31/445 (EP,CN,EA,KR,US); A61K38/47 (EP,CN,EA,US); A61K47/22 (EA,US);
A61P3/00 (EP); A61P43/00 (EP); A61P9/00 (EP);
C12Y302/01062 (CN); A61K9/0019 (EP); A61K9/20 (EP) (-)
C-Set:
A61K31/445, A61K2300/00 (EP,CN,US);
A61K38/47, A61K2300/00 (US,CN,EP)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2021/14]
Former [2020/35]AL,  AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  RS,  SE,  SI,  SK,  SM,  TR 
TitleGerman:DOSIERUNGSPLÄNE ZUR BEHANDLUNG VON MORBUS FABRY[2020/35]
English:DOSING REGIMENS FOR THE TREATMENT OF FABRY DISEASE[2020/35]
French:RÉGIMES DE DOSAGE POUR LE TRAITEMENT DE LA MALADIE DE FABRY[2020/35]
Examination procedure26.02.2021Examination requested  [2021/14]
26.02.2021Date on which the examining division has become responsible
25.05.2021Amendment by applicant (claims and/or description)
31.05.2024Despatch of a communication from the examining division (Time limit: M06)
18.12.2024Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
18.02.2025Reply to a communication from the examining division
Parent application(s)   TooltipEP12758017.3  / EP2683382
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the examination report
18.02.2025Request for further processing filed
18.02.2025Full payment received (date of receipt of payment)
Request granted
26.02.2025Decision despatched
The application is deemed to be withdrawn due to failure to reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report/Supplementary European search report
25.05.2021Request for further processing filed
25.05.2021Full payment received (date of receipt of payment)
Request granted
04.06.2021Decision despatched
Fees paidRenewal fee
23.03.2020Renewal fee patent year 03
23.03.2020Renewal fee patent year 04
23.03.2020Renewal fee patent year 05
23.03.2020Renewal fee patent year 06
23.03.2020Renewal fee patent year 07
23.03.2020Renewal fee patent year 08
23.03.2020Renewal fee patent year 09
12.03.2021Renewal fee patent year 10
14.01.2022Renewal fee patent year 11
12.01.2023Renewal fee patent year 12
03.01.2024Renewal fee patent year 13
06.01.2025Renewal fee patent year 14
06.01.2026Renewal fee patent year 15
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[XYI] WO2008121826  (AMICUS THERAPEUTICS INC et al.)
 [Y] WO9962517  (FAN JIAN QIANG et al.)
 [XYI] US2006153829  (FAN JIAN-QIANG et al.) [X] 1 * page 4, line 27 - line 28 * * page 13, line 27 - line 29 * * page 13, line 24 *[Y] 1-10 [I] 1-10
 [Y] US2010266571  (LOCKHART DAVID et al.) [Y] 1-10 * claim 5 *
 [Y] US2010291060  (STURK LISA MARIE et al.) [Y] 1-10 * example 3 * * claims 52-57 *
by applicant  FULLER ET AL., CLINICAL CHEMISTRY, vol. 51, 2005, pages 688 - 694
   ENG ET AL., AM. J. HUM. GENET., vol. 68, 2001, pages 711 - 722
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.